Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Deployment of in silico and in vitro Safety Assays in Early-Stage Drug Discovery

Published: Friday, July 20, 2012
Last Updated: Friday, July 20, 2012
Bookmark and Share
This article discusses the use of in silico and cell-based assays in de-risking compounds in the early chemistry space.

One of the main reasons for the cost explosion in drug development is the increase in attrition, especially in highly expensive later-stage clinical trials. Between 1990 and 2004, attrition increased to 70% in Phase II and 50% in Phase III, and it is estimated that of all compounds that make it into the clinic, only 11% reach the market. Some of these later stage failures can be explained by a few factors: a shift in market potential; targets in a more complex biological context and lack of efficacy; and the need for new drugs with better efficacy or safety profile than the current standard of care. Toxicity, however, is the main reason for attrition, accounting for 30% of compound failure in clinical trials and 40–60% failure in preclinical work.

As such, the pharmaceutical industry is greatly interested in reducing costly late-stage attrition by shifting compound failure earlier in the R&D pipeline and, if possible, even before preclinical in vivo studies. In fact, the National Research Council in its 2007 report “Toxicity Testing in the 21st Century: A Vision and a Strategy” calls for transforming toxicology “from a system based on whole-animal testing to one founded primarily on in vitro methods that evaluate changes in biologic processes using cells, cell lines, or cellular components, preferably of human origin.” And indeed, using in vitro assays to assess compound-induced toxicity has a long history dating back more than half a century; for example, the use of cells to measure the toxicity of sulphonamide drugs was published in 1941.

The full article is published online in Future Medicinal Chemistry and is free to access.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Systems Medicine – The Future Approach to Diseases
Review give insight into the future of understanding the body and its mechanisms through systems medicine.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
Mapping the Human Immune System
Researchers try to harness supercomputers to create the first map of the human immune system.
Microsatellites Linked to Cancer
DNA repeat stretches, called microsatellites, play a greater role in cancer progression and survival that previously thought.
Universal Flu Vaccine Designed by Scientists
An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos